Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond

被引:19
作者
Ansell, Stephen M. [1 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
关键词
STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; DISEASE; ABVD; HYBRID; ACTIVATION; CONJUGATE; THERAPY; TRIALS;
D O I
10.1002/ajh.24226
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hodgkin lymphoma is a rare lymphoid malignancy affecting similar to 9,200 new patients in the United States annually. Progress in the management of this disease over the past 50 years has been remarkable and the prognosis of this malignancy has changed from a uniformly fatal process to one in which the vast majority of patients are expected to be cured. This remarkable progress has been due to the use of combination approaches incorporating chemotherapy and radiation therapy, and now more recently antibody-drug conjugates and immune checkpoint inhibitors. The goal for the future is to develop treatment combinations that successfully treat all patients and markedly decrease the long-term side effects. (c) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:109 / 112
页数:4
相关论文
共 32 条
[11]  
Forero-Torres A, 2015, 2015 ASCO ANN M JUN
[12]   cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J].
Francisco, JA ;
Cerveny, CG ;
Meyer, DL ;
Mixan, BJ ;
Klussman, K ;
Chace, DF ;
Rejniak, SX ;
Gordon, KA ;
DeBlanc, R ;
Toki, BE ;
Law, CL ;
Doronina, SO ;
Siegall, CB ;
Senter, PD ;
Wahl, AF .
BLOOD, 2003, 102 (04) :1458-1465
[13]   Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma [J].
Gopal, Ajay K. ;
Chen, Robert ;
Smith, Scott E. ;
Ansell, Stephen M. ;
Rosenblatt, Joseph D. ;
Savage, Kerry J. ;
Connors, Joseph M. ;
Engert, Andreas ;
Larsen, Emily K. ;
Chi, Xuedong ;
Sievers, Eric L. ;
Younes, Anas .
BLOOD, 2015, 125 (08) :1236-1243
[14]   Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy [J].
Green, Michael R. ;
Rodig, Scott ;
Juszczynski, Przemyslaw ;
Ouyang, Jing ;
Sinha, Papiya ;
O'Donnell, Evan ;
Neuberg, Donna ;
Shipp, Margaret A. .
CLINICAL CANCER RESEARCH, 2012, 18 (06) :1611-1618
[15]   RETRACTED: Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappa B transcription factor (Retracted article. See vol 93, pg 3573, 1999) [J].
Gruss, HJ ;
Ulrich, D ;
Dower, SK ;
Herrmann, F ;
Brach, MA .
BLOOD, 1996, 87 (06) :2443-2449
[16]   A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma [J].
Johnston, Patrick B. ;
Inwards, David J. ;
Colgan, Joseph P. ;
Laplant, Betsy R. ;
Kabat, Brian F. ;
Habermann, Thomas M. ;
Micallef, Ivana N. ;
Porrata, Luis F. ;
Ansell, Stephen M. ;
Reeder, Craig B. ;
Roy, Vivek ;
Witzig, Thomas E. .
AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (05) :320-324
[17]   20 YEARS OF MOPP THERAPY FOR HODGKINS-DISEASE [J].
LONGO, DL ;
YOUNG, RC ;
WESLEY, M ;
HUBBARD, SM ;
DUFFEY, PL ;
JAFFE, ES ;
DEVITA, VT .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1295-1306
[18]   Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma [J].
Majhail, Navneet S. ;
Weisdorf, Daniel J. ;
Defor, Todd E. ;
Miller, Jeffrey S. ;
McGlave, Philip R. ;
Slungaard, Arne ;
Arora, Mukta ;
Ramsay, Norma K. C. ;
Orchard, Paul J. ;
MacMillan, Margaret L. ;
Burns, Linda J. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (10) :1065-1072
[19]  
Moskowitz CH, 2014, 2014 ASH ANN M DEC S
[20]   Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate [J].
Okeley, Nicole M. ;
Miyamoto, Jamie B. ;
Zhang, Xinqun ;
Sanderson, Russell J. ;
Benjamin, Dennis R. ;
Sievers, Eric L. ;
Senter, Peter D. ;
Alley, Stephen C. .
CLINICAL CANCER RESEARCH, 2010, 16 (03) :888-897